Effects of green tea supplementation on elements, total antioxidants, lipids, and glucose values in the serum of obese patients.The effects of L-arginine, alone and combined with vitamin C, on mineral status in relation to its antidiabetic, anti-inflammatory, and antioxidant properties in male rats on a high-fat diet.Changes in mineral status are associated with improvements in insulin sensitivity in obese patients following L-arginine supplementation.Current approach for detection of sub-clinical left ventricular dysfunction associated with chemotherapy.Coenzyme Q10 - A new player in the treatment of heart failure?Plasma homocysteine is a determinant of tissue necrosis factor-alpha in hypertensive patients.Cardioprotective effects of an active metabolite of furnidipine in 2 models of isolated heart and on in vivo ischemia–induced and reperfusion-induced arrhythmias in rats.Reimbursement of biosimilars in Poland: is there a link to health technology assessment?Influence of short-term L-arginine supplementation on carbohydrate balance in rats with ischemia-reperfusion syndrome.The role of magnesium in cardiac arrhythmiasPlasma total homocysteine is a determinant of carotid intima-media thickness and circulating endothelial progenitor cells in patients with newly diagnosed hypertensionThe influence of short-term l-arginine supplementation on rats’ muscular and hepatic cells in ischemia–reperfusion syndromeDielectric properties of keratin–water system in diabetic and healthy human fingernailsIs it possible to prevent chemotherapy-induced heart failure with cardiovascular drugs - the review of the current clinical evidencePhotosensitivity reactions in the elderly population: questionnaire-based survey and literature review
P50
Q36408345-B4EACDF1-0AC3-4C62-B563-3404C83FD959Q37491292-CAB5F8EE-676B-47DB-84EC-1FC0B339B1E4Q37585921-7B2A9F52-A10B-44EA-8700-CB4A07E24BCFQ38611165-6B3F6ACC-3251-4A23-9F9D-9DFAB8D88A92Q38900778-21853F3C-7DB6-476C-89A8-AE52E1171AB9Q46840982-DD79B687-ADD3-43A1-86A1-1843FC0BA6BBQ48968251-9D391151-7CE0-471F-AEC4-A8EE633E19B3Q53317811-44A51ADB-7C09-4BFB-A973-E03C41C7337CQ54496176-DC38C28C-7ECD-421C-8218-32FF030A5ACFQ60171614-F11E5B5A-638F-43C2-9842-A077D2AF53FDQ60171624-F03A403D-CF0A-4581-8843-DA393426CE73Q60171627-B259553F-4FFB-4A5F-9FE8-8A51CA3D1B7DQ60171640-5B70BA21-27F1-44B7-9B61-062792D9578BQ90353650-6D1DE793-FCB5-41FA-9D23-A314F7DCA16EQ90397770-EBBB5452-CE04-491B-B254-7C1A203BD927
P50
description
farmakolog kliniczny, profesor
@pl
hulumtuese
@sq
researcher
@en
ricercatrice
@it
wetenschapper
@nl
հետազոտող
@hy
name
Anna Jabłecka
@ast
Anna Jabłecka
@de
Anna Jabłecka
@en
Anna Jabłecka
@es
Anna Jabłecka
@nl
Anna Jabłecka
@pl
Anna Jabłecka
@sl
type
label
Anna Jabłecka
@ast
Anna Jabłecka
@de
Anna Jabłecka
@en
Anna Jabłecka
@es
Anna Jabłecka
@nl
Anna Jabłecka
@pl
Anna Jabłecka
@sl
altLabel
Anna Irena Jabłecka
@pl
prefLabel
Anna Jabłecka
@ast
Anna Jabłecka
@de
Anna Jabłecka
@en
Anna Jabłecka
@es
Anna Jabłecka
@nl
Anna Jabłecka
@pl
Anna Jabłecka
@sl
P214
P1153
6603259283
P1559
Anna Jabłecka
@pl
P21
P213
0000 0001 1219 4197
P214
P31
P3124
P496
0000-0001-7132-8159
P569
1954-01-01T00:00:00Z
P7859
viaf-163388800